Loading
Syntrix Pharmaceuticals
Syntrix Pharmaceuticals, near Seattle, develops SX-682, a tablet that blocks signals tumours use to gather immune-suppressing cells around themselves. It is in phase 2 trials, including in prostate cancer.
Also called: Syntrix Biosystems, Inc.Syntrix Biosystems
Overview
Syntrix Pharmaceuticals (Syntrix Biosystems, Inc.) of Auburn, Washington, develops SX-682, a small-molecule dual inhibitor of the chemokine receptors CXCR1 and CXCR2, which the company describes as inactivating immunosuppressive myeloid cells in the tumour microenvironment; it also has a pain programme. SX-682 is in phase 1 and phase 2 trials, among them NCT06228053, a Syntrix-sponsored phase 2 trial with enzalutamide in metastatic castration-resistant prostate cancer. Two 2026 National Cancer Institute SBIR awards fund a dose-expansion study of SX-682 alone and with decitabine in myelodysplastic syndromes and a phase 2 study with nivolumab and relatlimab in melanoma.
Headquarters
Auburn, WA, US
Scorecard
All companies#743of 1706 companies, score 3
- phase 1/2 +1
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR (R44) award 5R44CA291622-03: A Dose Expansion Study of SX-682 Alone and in Combination with Decitabine in MDS Patients | 2026 | $740K | reporter.nih.gov |
| Grant · NCI SBIR (R44) award 1R44CA306688-01A1: A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patients | 2026 | $407K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Products
1Phase 2Oral small-molecule inhibitor
SX-682 is an experimental tablet from Syntrix Pharmaceuticals that blocks the CXCR1 and CXCR2 receptors on immune-suppressing cells. It is in phase 2 trials, alone or with other medicines, in prostate cancer, lung cancer and other cancers.
Notes
- Company website (home and immuno-oncology pages) and the NIH RePORTER records read on 4 November 2026. The website says SX-682 is the only oncology therapeutic in development that blocks all parts of the CXCR1/2 axis; that is the company's claim.
Connected
7Similar pages
- TargetGATA2
Shares Myelodysplastic syndromes / neoplasms (MDS), Prostate cancer.
- TargetU2AF1
Shares Myelodysplastic syndromes / neoplasms (MDS), Prostate cancer.
- TreatmentCFI-400945
Shares Myelodysplastic syndromes / neoplasms (MDS), Prostate cancer.
cancers
fronts
drugs
Phase 2Oral small-molecule inhibitor
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
syntrixbio.com · 2
A source that has moved or gone is reported by the weekly link check. /audit/